About: Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
Creator	Wong, David Li, Xiaoxin Rica, Costa Eldem, Bora Joussen, Antonia »more»
source	Medline; PMC
abstract	PURPOSE: There is an urgent need to address how to best provide ophthalmic care for patients with retinal disease receiving intravitreal injections with anti-vascular endothelial growth factor agents during the ongoing global COVID-19 pandemic. This article provides guidance for ophthalmologists on how to deliver the best possible care for patients while minimizing the risk of infection. METHODS: The Vision Academy’s Steering Committee of international retinal disease experts convened to discuss key considerations for managing patients with retinal disease during the COVID-19 pandemic. After reviewing the existing literature on the issue, members put forward recommendations that were systematically refined and voted on to develop this guidance. RESULTS: The considerations focus on the implementation of steps to minimize the exposure of patients and healthcare staff to COVID-19. These include the use of personal protective equipment, adherence to scrupulous hygiene and disinfection protocols, pre-screening to identify symptomatic patients, and reducing the number of people in waiting rooms. Other important measures include triaging of patients to identify those at the greatest risk of irreversible vision loss and prioritization of treatment visits over monitoring visits where possible. In order to limit patient exposure, ophthalmologists should refrain from using treatment regimens that require frequent monitoring. CONCLUSION: Management of patients with retinal disease receiving intravitreal injections during the COVID-19 pandemic will require adjustment to regular clinical practice to minimize the risk of exposure of patients and healthcare staff, and to prioritize those with the greatest medical need. The safety of patients and healthcare staff should be of paramount importance in all decision-making.
has issue date	2020-04-23(xsd:dateTime)
bibo:doi	10.1007/s00417-020-04703-x
bibo:pmid	32328757
has license	cc-by
sha1sum (hex)	7cb43ae2083d08f2769a93724235c23963ffadd4
schema:url	https://doi.org/10.1007/s00417-020-04703-x
resource representing a document's title	Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
has PubMed Central identifier	PMC7179379
has PubMed identifier	32328757
schema:publication	Graefes Arch Clin Exp Ophthalmol
resource representing a document's body	covid:7cb43ae2083d08f2769a93724235c23963ffadd4#body_text
is schema:about of	named entity 'provide' named entity 'retinal disease' named entity 'patients' named entity 'FOCUS' named entity 'ACADEMY' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software